Compare AES Corp (AES) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs TransMedics Group Inc — how do they compare? AES Corp trades at $14.76 (market cap $10.49B), while TransMedics Group Inc trades at $89.43 (market cap $3.02B). The key difference: AES Corp is far larger — about 3.5× TransMedics Group Inc's market cap, and AES Corp pays a 4.79% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AES | TMDX | |
|---|---|---|
Market Cap | $10.49B | $3.02B |
Sector | Utilities | Technology |
52-Week High | $17.28 | $150.42 |
52-Week Low | $12.51 | $61.99 |
Enterprise Value | $40.75B | $3.41B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES Corporation trades at $14.73, up 0.2% with strong valuation metrics including P/E of 5.51 and P/S of 0.81. The company shows improving fundamentals with 2025 revenue of $12.23B and net income of $910M, though Q2 2026 earnings missed expectations. Technical indicators signal bearish momentum while analyst consensus leans toward Hold. The pending $33.4B acquisition by Global Infrastructure Partners and EQT creates significant near-term catalyst potential.
Investment outlook centers on acquisition completion offering upside to $15/share plus dividend yield. Risks include regulatory approval uncertainty and shareholder litigation. Strong cash flow generation and renewable energy investments support long-term growth, but debt levels remain elevated at 66.94% debt-to-asset ratio requiring monitoring.
TransMedics Group (TMDX) trades at $87.02, down 2.62% on the day, amid mixed earnings performance. The stock shows strong profitability with a 22.69% net margin and 36.28% ROE, but recent quarters saw misses on EPS expectations. Technicals are bullish with moving averages supporting upside, while oscillators signal caution. Recent news highlights an ongoing legal investigation into fiduciary duties by company directors.
The outlook is cautiously optimistic with a consensus price target of $99.57 implying 14% upside, supported by bullish analyst ratings. Key risks include earnings volatility, rising costs impacting margins, and potential legal overhangs from the fiduciary investigation. Revenue growth remains a positive catalyst, but investors should monitor execution against future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
